FDA Advisors Reverse Resolution on Weight-Loss Drug Qnexa

With the growing drawback of weight problems within the U.S. hastened by deep-seated roots stemming from a largely sedentary life-style and unhealthy consuming habits, it’s no surprise that a fast-repair continues to be the elusive carrot on a stick.
Pharmaceutical giants, including Arena Prescription drugs, Lorcaserin and Vivus Inc., are jostling for the possibility to be the primary firm to launch an FDA-accepted prescription weight-loss drug because the final, and only, accepted prescription drug of its kind hit the market in 1999.

The seek for a “magic tablet” has been hindered in current months as Vivus’ drug, Qnexa, was struck down by the FDA’s advisory committee last 12 months, citing direct connections to heightened danger of cardiovascular issues and beginning defects. In an obvious change of coronary heart, a panel of medical experts released a 20-2 vote in favor of Qnexa Wednesday, possible which means the FDA’s final decision later in the year can be to approve the drug.

SEE RELATED STORIES FROM THE WDM CONTENT NETWORK:

• First-ever Report Discusses Value of Weight problems to Individuals
• Contemporary and Health Initiative via Vending Machines
• Click here to learn the latest version of Enterprise Assessment USA

The drug manufacturer, primarily based out of Mountain View, California, addressed the unique health considerations by proposing monthly pregnancy checks for patients administered the drug, in addition to strictly managed distribution by registered pharmacies and specialized coaching for healthcare suppliers to better educate them on the dangers of the medication. Vivus also recommended implementing a program to intently monitor coronary heart risks in patients utilizing the drug.

"We're confident the Qnexa [risk management program] balances the safeguards whereas allowing entry for acceptable patients,” Dr. Barbara Troupin, Vivus' senior director of world medical affairs, told the committee. Qnexa combines the urge for food suppressant phentermine and anticonvulsant drug topiramate. Users lost an average of 10% of their body weight throughout scientific trials.

Over-the-counter weight reduction dietary supplements stay well-liked, despite remembers and damaging unwanted effects, including dozens of deaths linked to the Fen Phen craze of the ‘90s. Marketdata projects weight loss plan pill and meal replacement sales alone will complete $3.04 billion in yearly sales by 2014.